Argenx - Articles and news items

Argenx announces initial ARGX-113 Phase 1 study results

Industry news / 6 January 2016 / Victoria White

The objective of the Phase 1 study is to evaluate the safety and tolerability of ARGX-113 and to identify a potential dose for future Phase 2 studies…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+